{"id":"actinomycin-d","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":{"chemblId":"CHEMBL427947","moleculeType":"Small molecule","molecularWeight":"1255.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Actinomycin-D is an antibiotic that binds to the DNA double helix by intercalating between GC base pairs, thereby blocking RNA synthesis and protein production. This mechanism makes it effective as a chemotherapeutic agent against rapidly dividing cancer cells. It has been used clinically for decades, particularly in pediatric malignancies.","oneSentence":"Actinomycin-D intercalates into DNA and inhibits RNA polymerase, preventing transcription and leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:26.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wilms tumor"},{"name":"Rhabdomyosarcoma"},{"name":"Ewing sarcoma"},{"name":"Gestational trophoblastic disease"},{"name":"Testicular cancer"}]},"trialDetails":[{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT07466316","phase":"PHASE3","title":"A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":"Rhabdomyosarcoma","enrollment":342},{"nctId":"NCT06401330","phase":"PHASE3","title":"A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-04-15","conditions":"Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor","enrollment":1656},{"nctId":"NCT07449949","phase":"","title":"A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-10-30","conditions":"ORR, PFS, OS","enrollment":43},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":"Pleuropulmonary Blastoma","enrollment":110},{"nctId":"NCT05304585","phase":"PHASE3","title":"Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-08-04","conditions":"Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma","enrollment":205},{"nctId":"NCT00352534","phase":"PHASE3","title":"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2006-11-06","conditions":"Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor","enrollment":808},{"nctId":"NCT04994132","phase":"PHASE3","title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-09-14","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":118},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT04388839","phase":"PHASE2","title":"Evolutionary Therapy for Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-29","conditions":"Rhabdomyosarcoma","enrollment":12},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT04562558","phase":"NA","title":"Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"xiang yang","startDate":"2020-09-29","conditions":"Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor","enrollment":228},{"nctId":"NCT00945009","phase":"PHASE3","title":"Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2009-07-13","conditions":"Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor","enrollment":249},{"nctId":"NCT03669783","phase":"PHASE3","title":"Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2023-02-03","conditions":"Childhood Renal Tumor","enrollment":110},{"nctId":"NCT06028672","phase":"NA","title":"Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-12","conditions":"Gestational Trophoblastic Neoplasia","enrollment":40},{"nctId":"NCT03382158","phase":"","title":"International PPB/DICER1 Registry","status":"RECRUITING","sponsor":"Children's Hospitals and Clinics of Minnesota","startDate":"2016-12-06","conditions":"Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome","enrollment":3400},{"nctId":"NCT06020755","phase":"PHASE2","title":"Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-12","conditions":"Gestational Trophoblastic Neoplasia","enrollment":17},{"nctId":"NCT06699472","phase":"PHASE2","title":"A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-31","conditions":"Ewing Sarcoma, Myelosuppression","enrollment":22},{"nctId":"NCT01464606","phase":"NA","title":"International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospitals and Clinics of Minnesota","startDate":"2009-12-22","conditions":"Pleuropulmonary Blastoma","enrollment":156},{"nctId":"NCT01782339","phase":"PHASE2","title":"A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2012-05-01","conditions":"Germ Cell Tumour","enrollment":45},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT06309732","phase":"PHASE2","title":"GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2006-07","conditions":"Testicular Neoplasms","enrollment":36},{"nctId":"NCT04817956","phase":"PHASE2","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-01","conditions":"Cancer Metastatic","enrollment":3000},{"nctId":"NCT00354835","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-12-26","conditions":"Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma","enrollment":481},{"nctId":"NCT01535053","phase":"PHASE3","title":"Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2012-06-18","conditions":"Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor","enrollment":57},{"nctId":"NCT02639650","phase":"PHASE3","title":"Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor","status":"UNKNOWN","sponsor":"Weiguo Lv","startDate":"2016-03-01","conditions":"Gestational Trophoblastic Neoplasms","enrollment":214},{"nctId":"NCT04756713","phase":"PHASE3","title":"Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-11","conditions":"Gestational Trophoblastic Neoplasia, Molar Pregnancy, Gestational Trophoblastic Tumor, Non-Metastatic","enrollment":150},{"nctId":"NCT00075582","phase":"PHASE3","title":"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-09-04","conditions":"Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma","enrollment":390},{"nctId":"NCT00354744","phase":"PHASE3","title":"High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-07","conditions":"Sarcoma","enrollment":109},{"nctId":"NCT01823315","phase":"PHASE3","title":"Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia","status":"UNKNOWN","sponsor":"Ding Ma","startDate":"2012-12","conditions":"Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, Gestational Trophoblastic Tumor","enrollment":300},{"nctId":"NCT01014767","phase":"PHASE3","title":"Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2009-11","conditions":"Brain Cancer, Choroid Plexus Tumors","enrollment":27},{"nctId":"NCT03885388","phase":"PHASE2, PHASE3","title":"Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2019-03-08","conditions":"Gestational Trophoblastic Tumor, Effects of Chemotherapy, Drug Toxicity","enrollment":300},{"nctId":"NCT00003702","phase":"PHASE3","title":"Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"1999-06","conditions":"Good Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor","enrollment":240},{"nctId":"NCT01055314","phase":"PHASE2","title":"Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-01","conditions":"Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma","enrollment":175},{"nctId":"NCT00674193","phase":"","title":"Evaluating Dactinomycin and Vincristine in Young Patients With Cancer","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-02","conditions":"Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma","enrollment":158},{"nctId":"NCT00084838","phase":"PHASE2","title":"Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2003-02","conditions":"Central Nervous System Tumor, Pediatric","enrollment":25},{"nctId":"NCT00072280","phase":"PHASE2","title":"Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma","status":"TERMINATED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Sarcoma","enrollment":7},{"nctId":"NCT00002610","phase":"PHASE3","title":"Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-01","conditions":"Kidney Cancer","enrollment":203},{"nctId":"NCT01531244","phase":"PHASE1, PHASE2","title":"Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2014-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT00940524","phase":"PHASE1","title":"Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-07","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT00002995","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1997-08","conditions":"Sarcoma","enrollment":483},{"nctId":"NCT00900354","phase":"","title":"Pharmacokinetics of Dactinomycin in Young Patients With Cancer","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2006-06","conditions":"Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":50},{"nctId":"NCT00003958","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-09","conditions":"Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma","enrollment":702},{"nctId":"NCT00003688","phase":"PHASE2","title":"Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"1999-10","conditions":"Gestational Trophoblastic Tumor","enrollment":""},{"nctId":"NCT00541411","phase":"NA","title":"Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2003-06","conditions":"Ewing's Sarcoma","enrollment":10},{"nctId":"NCT00491946","phase":"PHASE4","title":"A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer","status":"UNKNOWN","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2004-06","conditions":"Cancer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Actinomycin-D","genericName":"Actinomycin-D","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Actinomycin-D intercalates into DNA and inhibits RNA polymerase, preventing transcription and leading to cell death. Used for Wilms tumor, Rhabdomyosarcoma, Ewing sarcoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}